Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Enfusion stock

Learn how to easily invest in Enfusion stock.

Enfusion, which produces Cloud-based investment management software, wrapped its IPO, selling 15.322 million shares at $17 per share, the high end of its announced price range.

Shares of Enfusion will begin trading on the NYSE later today under the ticker symbol ENFN, but shares are available for limit orders on Robinhood and other platforms.

How to buy shares in Enfusion

  1. Choose a platform. If you're a beginner, our stock trading platform picks below can help you choose.
  2. Open your account. Provide your personal information and sign up.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: ENFN in this case.
  5. Research stocks. The platform should provide the latest information available.
  6. Buy your stocks. Place a market order or limit order with your preferred number of shares. It's that simple.
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving license and a means of payment.

Our top picks for buying Enfusion stock

Best for beginners

Go to site
Commission-free stock trading
  • No-cost financial planning and automated investing
  • $0 commission on stocks, ETFs and options
  • Get up to $1,000 in stock when you fund a new account within 30 days

Top pick for new account bonus

Go to site
$200 in US stocks
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Get $100-$5,000 when you open an account with $5,000 to $1,000,000+

Top pick for interest on uninvested cash

Go to site
Easy access to diverse assets
  • Trade stocks, bonds, options, ETFs, crypto, Treasurys, collectibles, royalties
  • Earn 5.1% APY on your cash
  • Earn a $0.18 rebate on options, with no commissions and no per-contract fees

Is it a good time to buy Enfusion stock?

Only you can make the decision on the time to leap... but here's some supporting information and analysis.

Use our graph to track the performance of ENFN stocks over time.

Share price volatility

Over the last 12 months, Enfusion's shares have ranged in value from as little as $7.37 up to $11.563. A popular way to gauge a stock's volatility is its "beta".

ENFN.US volatility(beta: 1.01)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Enfusion's is 1.006. This would suggest that Enfusion's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Historical closes compared with the last close of $9.42

1 week (2024-04-18)1.95%
1 month (2024-03-27)1.84%
3 months (2024-01-25)11.74%
6 months (2023-10-26)14.18%
1 year (2023-04-27)12.41%
2 years (2022-04-27)-28.04%
3 years (2021-04-21)N/A

The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.

Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.

Buy Enfusion stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Ratings Available asset types Minimum deposit Stock trade fee Cash sweep APY Signup bonus
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Mutual funds, ETFs, Alternatives
$0
$0
Get up to $1,000 in stock
when you fund a new Active Invest account
Go to site
More Info
Tastytrade
Finder Score: 4.6 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $100-$5,000
when you open and fund an account with $5,000 to $1,000,000+
Highly commended for Best Derivatives Trading Platform award.
Go to site
More Info
Public.com
Finder Score: 4.1 / 5: ★★★★★
Public.com
★★★★★
Stocks, ETFs, Cryptocurrency, Art, Treasury Bills, Collectibles
$0
$0
5.1%
N/A
2.5% fee applies to all alternative asset transactions.
Go to site
More Info
Robinhood Gold
Finder Score: 4.3 / 5: ★★★★★
Robinhood Gold
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
5%
Get a free stock
when you successfully sign up and link your bank account.
Try Robinhood Gold for 30 days risk-free upon signup and earn a 5% APY on your uninvested cash, a 3% match on IRA contributions, up to $50,000 in instant deposits and more. Accounts are auto-downgraded after the trial period. Robinhood Gold is $5/month.
Go to site
More Info
Moomoo
Finder Score: 4.7 / 5: ★★★★★
Exclusive
Moomoo
★★★★★
Stocks, Options, ETFs
$0
$0
5.10%
Choose a 1.5% match or 7 free fractional shares
when you open a new account and meet funding requirements
No commission stock and ETF trading, with a chance to get a 1.5% cash reward match or 7 free fractional shares.
Go to site
More Info
Robinhood
Finder Score: 4.4 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
1.5%
Get a free stock
when you successfully sign up and link your bank account.
Trade stocks, options, ETFs and crypto without commissions on a user-friendly platform and earn 1.5% APY on your uninvested cash.
Go to site
More Info
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Is Enfusion under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Enfusion P/E ratio, PEG ratio and EBITDA

Enfusion's current stock price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 135x. In other words, Enfusion stocks trade at around 135x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of November 09, 2023 (20.44). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, Enfusion's P/E ratio is best considered in relation to those of others within the industry or those of similar companies.

Enfusion's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $18.5 million.

The EBITDA is a measure of a Enfusion's overall financial performance and is widely used to measure a its profitability.

To put that into context you can compare it against similar companies.

Frequently asked questions

More guides on Finder

Ask a Question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site